For the quarter ending 2025-09-30, LGNDZ has $1,476,772K in assets. $526,601K in debts. $139,376K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 139,376 | 67,669 | ||
| Assets held for sale (note 2) | - | 35,228 | ||
| Short-term investments | 525,146 | 177,351 | ||
| Accounts receivable, net | 57,560 | 41,288 | ||
| Inventory | 11,900 | 15,489 | ||
| Short-term portion of financial royalty assets, net | 12,416 | 10,276 | ||
| Income taxes receivable | 536 | 828 | ||
| Other current assets | 6,986 | 4,816 | ||
| Total current assets | 753,920 | 352,945 | ||
| Intangible assets, net | 233,535 | 250,133 | ||
| Goodwill | 101,541 | 101,541 | ||
| Long-term portion of financial royalty assets, net | 206,332 | 193,556 | ||
| Noncurrent derivative assets | 9,351 | 17,958 | ||
| Property and equipment, net | 3,466 | 3,632 | ||
| Lease right-of-use assets | 7,609 | 7,991 | ||
| Equity method investments | 42,000 | - | ||
| Other investments | 106,721 | 10,908 | ||
| Deferred income taxes, net | 9,526 | 829 | ||
| Other assets | 2,771 | 9,111 | ||
| Total assets | 1,476,772 | 948,604 | ||
| Current finance lease liabilities | - | 24 | ||
| Deferred revenue | - | 111 | ||
| Accounts payable | 3,679 | 8,584 | ||
| Liabilities related to assets held for sale (note 2) | - | 35,692 | ||
| Accrued liabilities | 24,084 | 17,464 | ||
| Income taxes payable | 1,284 | 305 | ||
| Current contingent liabilities | 268 | 1,465 | ||
| Current operating lease liabilities | 1,089 | 1,089 | ||
| Other current liabilities | 135 | - | ||
| Total current liabilities | 30,539 | 64,734 | ||
| Long-term deferred revenue | 0 | 0 | ||
| Long-term contingent liabilities | 3,569 | 4,097 | ||
| Long-term operating lease liabilities | 4,415 | 4,629 | ||
| Long-term portion of 2030 convertible senior notes, net | 445,493 | - | ||
| Deferred income taxes, net | 22,673 | 32,246 | ||
| Other long-term liabilities | 19,912 | 14,369 | ||
| Total liabilities | 526,601 | 120,075 | ||
| Common stock, 0.001 par value 60,000 shares authorized 19,656 and 19,106 shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 20 | 20 | ||
| Additional paid-in capital | 362,614 | 358,635 | ||
| Accumulated other comprehensive income (loss) | 9,322 | 8,494 | ||
| Retained earnings | 578,215 | 461,380 | ||
| Total stockholders equity | 950,171 | 828,529 | ||
| Total liabilities and stockholders equity | 1,476,772 | 948,604 | ||
LIGAND PHARMACEUTICALS INC (LGNDZ)
LIGAND PHARMACEUTICALS INC (LGNDZ)